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Evidence will be presented that the Alzheimer’s disease (AD) epidemic is new, the disease
being very rare in the 1900s. The incidence is increasing rapidly, but only in developed
countries. We postulate that the new emerging environmental factor partially causal of the
AD epidemic is ingestion of inorganic copper from drinking water and taking supplement
pills, along with a high fat diet. Inorganic copper can be partially directly absorbed and
elevate the serum free copper pool. The Squitti group has shown that serum free copper
is elevated in AD, correlates with cognition, and predicts cognition loss. Thus, our inorganic
copper hypothesis fits well with the Squitti group data. We have also shown that AD
patients are zinc deficient compared to age-matched controls. Because zinc is a neuronal
protective factor, we postulate that zinc deficiency may also be partially causative of
AD. We carried out a small 6 month double blind study of a new zinc formulation and
found that in patients age 70 and over, it protected against cognition loss. Zinc therapy
also significantly reduced serum free copper in AD patients, so efficacy may come from
restoring normal zinc levels, or from lowering serum free copper, or from both.
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INTRODUCTION
Cancer, heart disease, and stroke have increasingly become major
killers in our Western societies. We have looked for environmen-
tal factors behind the increased mortality from these diseases,
and we have found them. They include cigarette smoking, air
pollution, diets high in fats and sugars and lacking in fruits
and vegetables, and lack of exercise, to name but a few. Con-
siderable effort has gone into identifying and mitigating the
environmental factors causing so much mortality from these
diseases.
In stark contrast, a new disease epidemic has crept into our
midst, clearly also strongly caused by environmental factors, but
almost no effort has been made to find the environmental culprits
and mitigate them. Perhaps this is because this new disease does
not quickly kill, rather it only robs a large segment of our elderly
of their ability to function effectively. This new disease epidemic
is Alzheimer’s disease (AD), and its close cousin, mild cognitive
impairment (MCI).
Why do we say it’s a new epidemic? First, it is an epidemic,
with 10% of those aged 60, 20% of those aged 70% and 30% of
those aged 80 in the U.S. affected with the disease (Alzheimer’s
Association, 2010). There are over 5 million Americans with AD,
with an equal number with MCI, 80% of whom develop AD at
the rate of 15% per year. Second, it is new, because it didn’t exist
or was very rare prior to 1900, and developed a rapidly increasing
prevalence after about 1950.
The evidence that AD didn’t exist, or was rare, prior to 1900 is
quite good. In their book, Dying for a Hamburger, Waldman and
Lamb (Waldman and Lamb, 2005) examined this question. They
point out that Osler, a clinician who edited a textbook pulling
together all known diseases in the late 1800s, did not mention
an AD like disease, although one entire volume was devoted to
diseases of the brain (Osler, 1910). Gowers, who wrote a textbook
of neurology during this period, also did not describe an AD
like disease (Gowers, 1888). Most important, Boyd, who wrote a
textbook of pathology during the late 1800s, updated in the early
1900s, did not describe amyloid plaques neurofibrillary tangles,
hallmarks of AD brain pathology, in brains at autopsy (Boyd,
1938).
Some say that since AD is a disease of aging, there just were
not enough old people around in the period of the 1800s, so the
disease was not observed, or at least not noticed. It is not true
that elderly people weren’t around back then. Waldman and Lamb
showed that in 1911, half the French population were living to age
60, the age of onset of AD (Waldman and Lamb, 2005). I checked
the US census for 1900, and there were 3.2 million people over
age 60, at today’s rate providing 36.3 thousand AD cases, more
than enough to have been frequently seen in the clinics of Osler
and Gower, and to have been frequently encountered at autopsy
by Boyd.
Others say that the disease does not represent a “new” epi-
demic because now our ability to recognize it as a disease is
much better, in other words our “diagnostic ability” is now greatly
improved. While this could conceivably explain the failure of
clinicians, such as Osler and Gowers, to recognize the disease,
although this seems unlikely given their thoroughness, it can’t
explain why pathologists such as Boyd didn’t observe amyloid
plaques and neurofibrillary tangles in brains at autopsy.
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So one fact is we have a new epidemic. The second fact is
that the epidemic is primarily occurring in developed countries
(except for Japan), and not in undeveloped countries (Ferri et al.,
2005).
These two facts make it clear that something or some things,
newly present in the last 100 years in the environment of devel-
oped, but not undeveloped, countries is causing this epidemic
of AD. Waldman and Lamb come to this same conclusion, and
because they believed the new factor was beef eating and AD
was a prion disease acquired from beef, they named their book,
Dying for a Hamburger (Waldman and Lamb, 2005). Certainly
beef eating fits the criteria of being associated with development
over the last 100 years, but we find no evidence that AD is a prion
disease. Nevertheless, we believe Waldman and Lamb were on
the right track, because we believe a high fat diet is one causal
factor for the AD epidemic, and beef eating is associated with a
high fat diet. Grant has shown that AD prevalence is positively
correlated with dietary fat intake across many countries (Grant,
1997). However, we believe an additional factor plays a major
causal role for the AD epidemic. For our view on this additional
factor, read on.
OUR HYPOTHESIS THAT INTAKE OF INORGANIC COPPER IS A
MAJOR CAUSAL FACTOR IN THE AD EPIDEMIC
The major stimulus to our awareness that ingestion of inorganic
copper could be a risk factor for AD resulted from the studies
of Sparks and Schreurs, reported in 2003 (Sparks and Schreurs,
2003). In studies of a cholesterol fed rabbit model of AD, they
found that addition of as little as 0.12 ppm copper to the distilled
drinking water of the rabbits greatly enhanced both AD type
brain pathology, and cognition loss by the animals. By reference,
the Environmental Protection Agency in the U.S. allows up to
1.3 ppm copper in human drinking water, over 10 times that
causing toxicity in the rabbit AD model. Allowances for copper in
drinking water are similar, or higher, around the world. The work
of Sparks and Schreurs has been confirmed by them in other AD
models, including the mouse model (Sparks et al., 2006), and have
been confirmed by another group (Singh et al., 2013).
We emphasize that we are talking about ingestion of inorganic
copper as being toxic, not organic copper. Organic copper is
copper in food, safely bound to proteins. Organic copper is
absorbed from the intestine into the blood, and processed by the
liver, and put into safe channels. In contrast copper in drinking
water (or in pills containing copper) is a simple inorganic salt of
copper, not bound to anything. We have evidence that at least a
portion of inorganic copper is absorbed into the blood, bypasses
the liver, and contributes immediately to the “free copper” pool
in the blood (Hill et al., 1986). A small increase in copper in food,
equivalent to 0.12 ppm, would be trivial and completely non-
toxic, whereas it is exquisitely toxic in drinking water, as shown
in the rabbit model.
The size of the “free copper” pool in the blood is very impor-
tant in AD, as shown by Squitti et al. (2005). Depending on
how it is measured, about 65–85% of the copper in blood is
covalently bound in ceruloplasmin (Cp), a copper containing
protein secreted into the blood by the liver, and is safe copper. The
remainder is loosely bound to albumin and some other molecules,
and is called “free copper”. The Squitti group has shown that
blood free copper levels in AD are significantly elevated compared
to age matched controls (Squitti et al., 2005), that free copper
levels are inversely correlated with cognition measure in AD (the
higher the free copper, the worse the cognition measures) (Squitti
et al., 2006), and are positively correlated with loss of cognition
over time (the higher the free copper, the greater the loss of
cognition) (Squitti et al., 2009). Thus, it is very rational that
addition to the free copper pool by ingestion of inorganic copper,
because some of it immediately increases the free copper pool,
could be a risk factor for AD causation.
The level of total plasma copper in AD patients versus age
matched controls should not be confused with the levels of blood
free copper we first discussed. Some authors have found total
serum copper elevated in AD, while others have not. But the
relevant finding is that blood free copper is elevated in AD.
So ingestion of inorganic copper in drinking water could be
a risk factor in AD, but are humans ingesting inorganic copper
in their drinking water? The answer is yes, it is being leached
from their copper plumbing! Looking back at the time course
of the AD epidemic it is remarkable how closely it parallels the
explosive use of copper plumbing in developed countries. Copper
plumbing began to be used in the early 20th century, but was
curtailed by World War I and then II. After 1950 copper plumbing
took off, and now 90% of U.S. homes have copper plumbing.
Similarly the AD epidemic took off in the latter half of the 20th
century, but only in developed countries. Copper plumbing is not
used very much in undeveloped countries, because of its expense.
Japan is an interesting exception that supports the copper in
drinking water causation hypothesis. It is a developed country,
but with a lower rate of AD (Ueda et al., 1992), and has shunned
copper plumbing for fear of toxicity. Yet, when Japanese migrate
to Hawaii, where copper plumbing is used, they developed the
higher rate of AD seen in other developed countries (White et al.,
1996).
We stated above that leaching of copper from copper plumbing
into drinking water is a risk factor of AD, but what is our evidence
that copper is actually leached into drinking water in significant
amounts? Our evidence is that we have measured it. We wanted
to make sure our patients with Wilson’s disease, a disease of cop-
per toxicity, weren’t ingesting excessive copper in their drinking
water. These patients came from all over N. America, attracted
to our clinic because of new Wilson’s disease treatments we were
developing. In a sample of drinking water from 280 homes, we
found about a third were higher than the 0.1 ppm causing toxicity
in the rabbit AD model, about one third were 0.01 ppm or lower,
a level we view as safe, and about one third were between 0.01 and
0.1 ppm, an area of unknown safety (Brewer, 2011). So people are
ingesting plenty of inorganic copper from their drinking water,
which according to the rabbit AD model could account for the
high and increasing prevalence of AD.
There is another source of inorganic copper leading to high
ingestion in the developed world, and that is use of supplement
pills containing copper. As with copper in drinking water, the
copper in pills is a simple salt, such as copper sulfate, and is thus
inorganic. Morris et al. (2006) did a study in Chicago of nutrient
intake, and cognition, over a period of years. They found that
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those in the highest quintile of copper intake, if they also ate a
high fat diet, lost cognition at six times the rate of other groups.
People were in the highest quintile of copper intake because they
took supplement pills containing copper.
One can also build a case for the other risk factors for AD
tying into the copper hypothesis. We believe another major risk
factor for AD is a high fat diet (Grant, 1997). Copper oxidizes
certain fat molecules into derivatives that are toxic to neurons.
Elevated homocysteine levels are a risk factor for AD (as they are
for atherosclerosis) (Seshadri et al., 2002). Homocysteine interacts
with copper to oxidize cholesterol to an intermediate damaging to
neurons. The apoliprotein E4 (apoE4) allele is a risk factor for
AD, while apoE2 is protective and apoE3 neutral (Miyata and
Smith, 1996). Apoliprotein may help remove copper from the
brain, and apoE4 has no copper binding cysteines, apoE3 one, and
apoE2 two. Certain hemochromatosis (Moalem et al., 2000) and
transferrin (Zambenedetti et al., 2003) alleles increase risk for AD.
These genes affect iron levels, and iron, like copper, is a transition
element that produces oxidant radicals. Oxidant damage is a
predominant type of damage in the AD brain. Recently it has been
shown that certain alleles of the ATP7B gene, also known as the
Wilson’s disease gene, increase risk for AD (Bucossi et al., 2011,
2012). This is further direct support of our hypothesis, because
this gene controls free copper levels.
Recently there has been some direct studies that strongly
support a critical role for copper toxicity in the AD brain. It has
been shown that “labile copper” is elevated in the AD brain, and
that this elevation is associated with oxidant pathology in the AD
brain (James et al., 2012).
In summary, we believe our hypothesis that ingestion of inor-
ganic copper is a major risk factor for AD is well supported.
Recounting the network of supporting data around this hypoth-
esis that constitutes good support, we have the observation that
trace amounts of inorganic copper in drinking water greatly
enhances AD pathology and cognition loss in AD animal models,
we have the concordance of the AD epidemic and use of copper
plumbing, the data showing toxic levels of copper in drinking
water all over N. America, the data of Morris et al. (2006)
showing cognition loss in those using copper supplements, the
data of Squitti et al. (2005) showing a high serum free copper
in AD patients, the data showing that gene mutations potentially
influencing copper levels increase AD risk, and the direct data
showing that “labile copper” is elevated in the AD brain.
Some authors have concluded the opposite, that copper defi-
ciency is a causal factor in AD. An example of this is Klevay (2008),
who hypothesize just that, that AD is copper deficiency. However,
this hypothesis is not well thought out, since AD patients display
none of the manifestations of copper deficiency, which are a very
low serum copper, anemia and bone marrow depression, and
myelopolyneuropathy neurologic syndrome. Another example is
Kessler et al. (2008) who gave copper to AD patients, and claimed
to see no worsening. They saw no improvement either, which dis-
proved their hypothesis that patients were suffering from copper
deficiency. We believe that ingestion of a high fat diet is another
important risk factor for AD, and that these two, ingestion of
inorganic copper plus a higher fat diet, set the stage on which the
other risk factors act.
It is sometimes said that a hypothesis is only useful if it can
be tested. It is a little hard to test this one definitively. The AD
animal model studies have probably gone as far as one can go with
animal studies. It is unethical to give humans potentially toxic
inorganic copper. Epidemiologic studies could be designed, but
these end up showing associations, which don’t prove causation.
Inorganic copper ingestion could be prevented in a large sample
of elderly (people age 60 or over), and AD outcomes compared
with an equally large sample of controls who continued ingestion
of inorganic copper at their normal rates, but this would take years
to complete, and be quite expensive. In the meantime, those who
believe this hypothesis is likely to be true, would be well-advised
to limit ingestion of inorganic copper.
OUR HYPOTHEIS THAT ZINC DEFICIENCY IS A RISK FACTOR
FOR AD AND COGNITION CAN BE STABLIZED BY ZINC
SUPPLEMENTATION
As people grow older, they become relatively zinc deficient
compared to younger people, as measured by serum zinc levels.
To evaluate the zinc status of AD patients we did a study on
AD patients and age-matched controls with Earl Zimmerman
and his group at Albany, NY. Because elderly people take many
mineral supplements, to make sure supplements weren’t affect-
ing the results, we stopped all supplements use one month
prior to the study. In 29 age-matched controls, mean serum
zinc was 82.7 µg/dl, as expected well below that of younger
people, which runs around 100 µg/dl. But the mean serum
zinc of 29 AD patients was 76.2 µg/dl, significantly less than
the mean of age-matched controls (Brewer et al., 2010). Baum
et al. (2010) have also found zinc deficiency in serum of AD
patients.
The fact that zinc levels are elevated in the AD brain led to
early speculation that zinc excess and zinc toxicity was a factor in
AD. However, now it is realized that amyloid plaques bind zinc
avidly, and this causes an increase brain zinc in AD. The uptake of
zinc by plaques is another cause of diminished zinc availability to
neurons.
Zinc has many important protective roles in neurons. For
example, it helps quench glutamate-stimulated neuronal firing,
preventing damage from excessive firing (Takeda, 2010). It also
inhibits calcineurin, which if too active, has downstream adverse
effects (Crouch et al., 2011). Serum zinc, when it is low, is a
reliable indicator of systemic zinc deficiency. But the brain in AD
may suffer even more from zinc deficiency than indicated by the
serum levels. That is because the amyloid plaques in the AD brain
are avid binders of zinc, and may make zinc even less available for
neurons.
Additional insight and credibility for the hypothesis that the
AD neuron is zinc deficient comes from the studies of the zinc
transporter-3 (ZnT3). This transporter is the zinc pump that
loads neuronal vesicles with zinc, the vesicles that are discharged
into the synapse with neuronal firing. ZnT3 knockout mice
exhibit deficits in memory and learning at 6 months of age, and
are said to be “a phenocopy of the synaptic and memory deficits
of AD” (Adlard et al., 2010). These same authors also found
that ZnT3 levels decreased with aging in the brains of mice and
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humans, and decreased significantly more with aging in the brains
of AD patients compared to age-matched controls.
For all these reasons, we hypothesize that zinc deficiency is a
risk factor in AD, that is, a factor which can precipitate, or at
least assist, cognitive decline. Given this hypothesis, it seemed
reasonable to evaluate the possible beneficial effect of zinc sup-
plementation.
In reviewing the literature, it turned out zinc supplementation,
both oral and parenteral, was tried in open label studies in 1991
by Constantinidis (1992). He reported excellent efficacy, although
the trials were uncontrolled. Corona et al. (2010) have also
reported beneficial effects of zinc supplementation in a rodent AD
model.
In our trial, we used a new zinc formulation developed by
myself and a company, Adeona Pharmaceuticals. I had previously
developed zinc acetate capsules, called Galzin, and had them
FDA approved for treating Wilson’s disease. The two problems
with Galzin were, first, it had to be taken away from food and
second, it had to be taken multiple times a day if one wanted to
achieve around the clock plasma zinc elevations. The new zinc
formulation employed a zinc binding agent that released the zinc
slowly, so it wasn’t irritating to the stomach, and also achieved
around the clock plasma zinc elevation.
The study was a placebo controlled 6 month trial in mild
to moderate AD patients (Brewer, 2012). Thirty AD patients
received 150 mg once daily of the new zinc formulation, and 30
age-matched controls received matching placebo. When giving
zinc in high dose like this, one has to be concerned about
inducing copper deficiency, which if allowed to become severe,
can lead to a severe neurologic syndrome. For that reason we
regularly monitored serum Cp, a good measure of copper sta-
tus, as well as hemoglobin levels, anemia being one of the first
manifestations of copper deficiency. During the 6 month study
only one patient had zinc dose reduced because of a decreas-
ing Cp. Endpoints were increased serum zinc, decreased serum
free copper, and better cognitive scores compared to controls.
Cognition was measured by Alzheimer’s Disease Assessment
Scale for Cognition (ADAS-cog), Clinical Dementia Rating Scale,
Sum of Boxes (CDR-SOB), and Mini Mental State Examination
(MMSE).
We anticipated a possible decrease in serum free copper with
zinc therapy because zinc blocks the absorption of copper in the
intestine. This is the basis of using zinc as a therapy for Wilson’s
disease, an inherited disease of copper accumulation and copper
toxicity.
We found serum zinc significantly increased and serum free
copper significantly decreased in zinc treated patients versus
controls. All three cognition scores were in a favorable direction in
the zinc treated group versus controls, but none were significant,
although CDR-SOB was close at p = 0.1. Looking at the data post
hoc, we realized cognition was relatively stable in controls until
age 70, when it began deteriorating much more rapidly, while
zinc treated patients remained relatively stable at age 70 and over.
We reanalyzed the data on those age 70 and over, and the 15 age
matched controls showed significant cognition loss compared to
the 14 AD patients, with ADAS-Cog at p = 0.037, CDR-SOB at p =
0.032, and MMSE close to significant at p = 0.067 (Brewer, 2012).
Thus, we conclude from this trial that zinc supplementation
will significantly stabilize cognition in AD patients age 70 and
over. We believe it will also stabilize cognition in younger patients,
but it is harder to show it statistically because controls are deteri-
orating so slowly before age 70. This study should be confirmed
by a larger study, and carried out longer, to evaluate whether the
stabilization by zinc therapy is maintained long term.
Assuming zinc therapy has efficacy in this study, the mech-
anism could be restoration, or partial restoration, of protective
zinc in the neuron, or lowering of toxic tree copper levels. Or
perhaps both mechanisms are operative since we achieved both.
Thus, at this point we can’t be certain that zinc deficiency is a
risk factor in AD, because zinc supplementation may be acting
through lowering serum free copper.
SUMMARY
We point out that we have a serious new epidemic of AD, partic-
ularly in developed countries, that is robbing a large portion of
our elderly of their golden years. We hypothesize that ingestion
of inorganic copper from drinking water and supplement pills,
together with a high fat diet, are major causal factors in the
epidemic. We show that copper from copper plumbing is leached
into drinking water at high enough levels to be causal for AD,
according to a rabbit AD model. We advise those who believe
the hypothesis to be correct to curtail their ingestion of inorganic
copper.
We also hypothesize that zinc deficiency is a risk factor for
AD, and show that in patients age 70 and over, 6 months of zinc
therapy significantly decreased cognition loss compared to age
matched controls.
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